Sanofi (NASDAQ:SNY – Get Free Report) and Adherex Technologies (NASDAQ:FENC – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, earnings, dividends and analyst recommendations.
Valuation and Earnings
This table compares Sanofi and Adherex Technologies”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanofi | $50.98 billion | 2.32 | $8.84 billion | $2.02 | 24.11 |
| Adherex Technologies | $44.64 million | 8.94 | -$9.74 million | ($0.13) | -87.18 |
Sanofi has higher revenue and earnings than Adherex Technologies. Adherex Technologies is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Sanofi and Adherex Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanofi | 0 | 12 | 8 | 1 | 2.48 |
| Adherex Technologies | 1 | 1 | 4 | 0 | 2.50 |
Sanofi currently has a consensus target price of $53.00, indicating a potential upside of 8.83%. Adherex Technologies has a consensus target price of $17.00, indicating a potential upside of 49.99%. Given Adherex Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe Adherex Technologies is more favorable than Sanofi.
Insider and Institutional Ownership
14.0% of Sanofi shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 10.7% of Adherex Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Sanofi has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Adherex Technologies has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500.
Profitability
This table compares Sanofi and Adherex Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanofi | 8.70% | 15.16% | 8.48% |
| Adherex Technologies | -6.09% | -5.71% | -2.37% |
Summary
Sanofi beats Adherex Technologies on 9 of the 15 factors compared between the two stocks.
About Sanofi
Sanofi is a France-based global biopharmaceutical company that researches, develops, manufactures and markets medicines and vaccines. Its work spans areas including immunology, oncology, rare diseases and neurology, as well as preventive vaccines. The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron, and vaccines for diseases such as influenza and meningitis. Sanofi serves patients and healthcare providers in markets around the world. Sanofi traces its origins to a company established in France in 1973.
About Adherex Technologies
Adherex Technologies was a biotechnology company focused on developing treatments for cancer. In 2014, the company changed its name to Fennec Pharmaceuticals Inc.; Fennec later adopted the Nasdaq ticker FENC. Fennec is a commercial-stage biopharmaceutical company focused on therapies that address complications of cancer treatment. Its principal product is PEDMARK, a sodium thiosulfate injection approved in the United States to reduce the risk of cisplatin-related hearing damage in certain pediatric patients with cancer.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
